|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Matthieu Frechin||CEO & Non-Independent Chairman of the Board||490,68k||N/D||1969|
|Mr. Dominique Derveaux||Chief Operations Officer||382,12k||N/D||1969|
|Mr. Alain Masson||Deputy CEO & Pharmacist Manager||189,38k||N/D||1962|
|Mr. Regis Vimal du Monteil||Chief Financial Officer||N/D||N/D||1965|
|Philippe Gruet||Chief Scientific Officer||N/D||N/D||N/D|
|Sandrine Perrier||Chief Information Officer||N/D||N/D||N/D|
|Laurent Thore||Director of Partnerships, Legal Affairs & Risks||N/D||N/D||N/D|
|Xavier Berthet||Director of Group Communications||N/D||N/D||N/D|
|Mr. Hans Hollegien||Group Director of Marketing||N/D||N/D||N/D|
|Ms. Isabelle Proust-Cabrera||Group Director of Human Resources||N/D||N/D||N/D|
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
L'ISS Governance QualityScore di Vetoquinol SA al 1 dicembre 2023 è 10. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 9; diritti degli azionisti: 8; retribuzione: 8.